Thermo Fisher sells $3.8 billion of senior notes to help fund Clario acquisition
Thermo Fisher issued four series of senior notes in a public offering on February 12, 2026, totaling $3.8 billion in principal. The company expects net proceeds of about $3.76 billion and plans to use them to pay part of the cash consideration for its pending Clario Acquisition, which still requires customary closing conditions and regulatory approvals.
Key points
- Four note series totaling $3.8 billion: $1.0 billion due 2031, $750 million due 2033, $1.3 billion due 2036 and $750 million due 2046
- Expected net proceeds of approximately $3.76 billion after underwriting discounts and estimated offering expenses
- Proceeds intended to pay a portion of the cash consideration for the previously announced Clario Acquisition, which is subject to closing conditions and regulatory approvals
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.